Literature DB >> 16237529

The protective effects of incadronate on inflammation and joint destruction in established rat adjuvant arthritis.

Hongpu Zhao1, Shangli Liu, Dongsheng Huang, Qiuyu Xu, Toshihide Shuto, Yukihide Iwamoto.   

Abstract

The effects of a new generation bisphosphonate, incadronate, in established adjuvant arthritis rats were evaluated according to the arthritis index, hind paw volume, and radiological and histopathological examinations. Incadronate suppressed the radiological and histopathological changes of hind paws, as well as the joint swelling in a dose-dependent manner. In contrast, the arthritis control rats showed drastic joint inflammation, marked destruction of bone and articular cartilage. The remains of articular cartilage lost Safranin O staining, and were attached with numerous TRAP-positive multinuclear cells. Some of resorption lacunas could be seen at the cartilage matrix nearby the TRAP-positive multinuclear cells. As regards the chondroprotective effects of bisphosphonates, we speculate that it is probably concerned with the inhibition of the chondroclasts. These data indicate that bisphosphonates may be a class of effective agent that can be considered for treatment of various arthritic conditions, including human rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16237529     DOI: 10.1007/s00296-005-0061-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  31 in total

Review 1.  Bisphosphonates: mechanisms of action.

Authors:  G A Rodan; H A Fleisch
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

2.  Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis.

Authors:  N V Podworny; R A Kandel; R C Renlund; M D Grynpas
Journal:  J Rheumatol       Date:  1999-09       Impact factor: 4.666

3.  Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

Authors:  T Mashiba; T Hirano; C H Turner; M R Forwood; C C Johnston; D B Burr
Journal:  J Bone Miner Res       Date:  2000-04       Impact factor: 6.741

4.  The subchondral bone in osteoarthritis and rheumatoid arthritis of the knee. A histological and microradiographical study.

Authors:  T Havdrup; A Hulth; H Telhag
Journal:  Acta Orthop Scand       Date:  1976-06

5.  Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra.

Authors:  Satoshi Komatsubara; Satoshi Mori; Tasuku Mashiba; Masako Ito; Jiliang Li; Yoshio Kaji; Tomoyuki Akiyama; Kensaku Miyamoto; Yongping Cao; Jun Kawanishi; Hiromichi Norimatsu
Journal:  J Bone Miner Res       Date:  2003-03       Impact factor: 6.741

6.  Effect of clodronate on established adjuvant arthritis.

Authors:  T Osterman; K Kippo; L Laurén; R Hannuniemi; R Sellman
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

7.  A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.

Authors:  D Thiébaud; P Jaeger; C Gobelet; A F Jacquet; P Burckhardt
Journal:  Am J Med       Date:  1988-08       Impact factor: 4.965

8.  Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes.

Authors:  R W Kinne; C B Schmidt-Weber; R Hoppe; E Buchner; E Palombo-Kinne; E Nürnberg; F Emmrich
Journal:  Arthritis Rheum       Date:  1995-12

9.  Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint.

Authors:  M Bromley; D E Woolley
Journal:  Arthritis Rheum       Date:  1984-09

Review 10.  Treatment of tumor-induced hypercalcemia: a solved problem?

Authors:  Jean-Jacques Body; Isabelle Mancini
Journal:  Expert Rev Anticancer Ther       Date:  2003-04       Impact factor: 4.512

View more
  1 in total

1.  RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro.

Authors:  Karen A Sutherland; Helena L Rogers; Denise Tosh; Michael J Rogers
Journal:  Arthritis Res Ther       Date:  2009-04-30       Impact factor: 5.156

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.